On Nov 06, major Wall Street analysts update their ratings for $BioNTech (BNTX.US)$, with price targets ranging from $110 to $145.
Morgan Stanley analyst Terence Flynn maintains with a buy rating, and maintains the target price at $145.
Evercore analyst Cory Kasimov maintains with a hold rating, and adjusts the target price from $100 to $110.
TD Cowen analyst Yaron Werber maintains with a hold rating, and maintains the target price at $122.
Oppenheimer analyst Jay Olson maintains with a hold rating.
Leerink Partners analyst Daina Graybosch maintains with a buy rating.
Furthermore, according to the comprehensive report, the opinions of $BioNTech (BNTX.US)$'s main analysts recently are as follows:
The firm has modified its estimates following the release of Pfizer's Comirnaty results and observed vaccine script trends for Comirnaty, Spikevax, and mResvia.
The firm observed that while the financial results surpassed expectations and guidance was maintained, the emphasis has now shifted to the company's oncology pipeline. This comes with anticipation for several significant results from the mid to late-stage pipeline expected in the fourth quarter of 2024 and the full year of 2025.
Here are the latest investment ratings and price targets for $BioNTech (BNTX.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
